Digbi Health and Novo Nordisk Pilot Testing Genetic and Gut Microbiome-Based Digital Solutions for Prevention of Obesity and Related Cardiometabolic Conditions
The pilot will examine whether multiomic and lifestyle data can predict whether a person is at high or low risk of obesity, based on Digbi's user population.
MOUNTAIN VIEW, Calif., August 22, 2022 /Digbi Newswire/ -- Digbi Health, leader in gut microbiome and genetic-based connected care solutions, is enrolled in Novo Nordisk's Global Prevention Accelerator Program to pilot test solutions for the prevention of obesity and related cardiometabolic conditions.
Digbi Health was selected based on a set of criteria including the ability to make a global impact and provide scalable digital solutions that can be adapted for local populations.
The Prevention Accelerator
In 2021, Novo Nordisk's Global Prevention Accelerator invited startups developing digital solutions to submit proposals outlining how they can enable individuals and communities to predict and prevent obesity. The Prevention Accelerator supports selected organizations with funding to pilot their solutions with Novo Nordisk.
Digbi Health has a unique artificial intelligence technology and we look forward to seeing it tested and gaining learnings from the pilot.
— Katrine Luisa DiBona, Head of Public Affairs and Sustainability, Novo Nordisk
What the pilot will examine
The specific pilot will examine whether it is possible, using multiomic and lifestyle data, to predict if a person has a high or low risk of obesity. The pilot will be based on the large population of Digbi users.
Phase I of the pilot wraps up at the end of September 2022, with the aim of moving into a next phase focused on scaling the Digbi Health solution to demonstrate large-scale validation.
Why ancestry and biology matter
Although it is known that obesity and cardiometabolic disease risks vary significantly by gender and ancestry and are linked to genetics and the gut microbiome, current weight management and obesity treatment programs largely ignore these critical signals in developing care protocols.
Digbi Health, working with leading employers, payers and pharmaceutical companies, has pioneered the use of AI and scientifically validated genome and gut microbiome signals, along with financial, family and work determinants of health, to identify, treat and support individuals struggling with weight and co-occurring digestive and cardiometabolic conditions.
Digbi Health is leading, through innovation, the development of personalized food-as-medicine treatment plans that target the root cause of GI and associated obesity and cardiometabolic illnesses. We are excited to collaborate with Novo Nordisk — the leading pharmaceutical company that is committed to the prevention and treatment of obesity — and together we can deliver economical and scalable solutions worldwide.
— Ranjan Sinha, CEO, Digbi Health
Multiomics is an approach where data sets of different omic groups are combined during analysis, such as genomics, proteomics, transcriptomics, epigenomics and microbiomics.
Originally distributed via PR Newswire.
About Digbi Health
Digbi Health is the precision biology care company unifying metabolic and inflammatory care — including obesity, cardiometabolic, gastrointestinal, and inflammatory disorders. These illnesses share a root cause: a mismatch between an individual's biology and the one-size-fits-all lifestyle guidance they've been given. Digbi combines the gut microbiome, genetics, advanced blood biomarkers, and continuous digital health data to build a unique biological profile for each individual and identify what is driving their disease. AI then personalizes lifestyle treatment and, when needed, clinical treatment, delivered through the first precision-biology AI-orchestrated national telehealth platform. Through Digbi Labs, we invest in our vision of making chronic illness optional and advancing healthspan — partnering with leading universities, pharmaceutical companies, and scientific and clinical laboratories, running distributed human trials and publishing peer-reviewed research on genetics, the gut microbiome, and the use of AI to deliver care that is safe, cost-effective, and accessible. Digbi's healthcare cost reduction is documented in multiple peer-reviewed actuarial claims studies. Digbi is accessible to 30 million individuals through more than 300 employers and health plans.
SOURCE Digbi Health
- Novo Nordisk
- Obesity Prevention
- Multiomics
- Gut Microbiome
- Pharma Partnership